{"id":12448,"date":"2020-10-27T17:22:18","date_gmt":"2020-10-27T08:22:18","guid":{"rendered":"http:\/\/cell.brc.riken.jp\/ja\/?page_id=12448"},"modified":"2025-10-06T09:37:43","modified_gmt":"2025-10-06T00:37:43","slug":"covid-19-research","status":"publish","type":"page","link":"http:\/\/cell.brc.riken.jp\/ja\/covid-19-research","title":{"rendered":"COVID-19 \u95a2\u9023\u7d30\u80de"},"content":{"rendered":"

1\uff09\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u306b\u5bfe\u3059\u308b\u7406\u7814BRC\u306e\u53d6\u308a\u7d44\u307f<\/strong><\/p>\n

\u7406\u7814\u30d0\u30a4\u30aa\u30ea\u30bd\u30fc\u30b9\u7814\u7a76\u30bb\u30f3\u30bf\u30fc(\u7406\u7814BRC)\u306f\u3001\u907a\u4f1d\u5b50\/\u7d30\u80de\/\u30de\u30a6\u30b9\u500b\u4f53\u306e\u4e09\u3064\u306e\u751f\u547d\u968e\u5c64\u306e\u30ea\u30bd\u30fc\u30b9\u30921\u6a5f\u95a2\u3067\u53d6\u308a\u63c3\u3048\u305f\u3001\u4e16\u754c\u7684\u306b\u3082\u30e6\u30cb\u30fc\u30af\u306a\u30ea\u30bd\u30fc\u30b9\u6a5f\u95a2\u3067\u3059\u3002\u3053\u306e\u7279\u5fb4\u3092\u6d3b\u304b\u3057\u3066\u3001\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u306e\u7d71\u5408\u7684\u306a\u7814\u7a76\u306e\u4fc3\u9032\u306e\u305f\u3081\u3001\u611f\u67d3\u75c7\u306e4\u3064\u306e\u30b9\u30c6\u30fc\u30b8\uff08\u2460\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u30fb\u5897\u6b96\u3001\u2461\u767a\u75c7\u30fb\u751f\u4f53\u9632\u5fa1\u3001\u2462\u91cd\u75c7\u5316\u3001\u2463\u6cbb\u7642\u30fb\u4e88\u9632\uff09\u306e\u7814\u7a76\u958b\u767a\u306e\u9375\u3068\u306a\u308b\u30d0\u30a4\u30aa\u30ea\u30bd\u30fc\u30b9\u3092\u53ce\u96c6\u30fb\u6574\u5099\u3057\u3001\u60c5\u5831\u767a\u4fe1\u3057\u3066\u3044\u304d\u307e\u3059\u3002<\/p>\n

COVID-19 \u95a2\u9023\u30de\u30a6\u30b9\u30ea\u30bd\u30fc\u30b9(\u5b9f\u9a13\u52d5\u7269\u958b\u767a\u5ba4\uff09<\/a><\/p>\n

SARS-CoV-2 relevant human genes(\u907a\u4f1d\u5b50\u6750\u6599\u958b\u767a\u5ba4\uff09<\/a><\/p>\n

\n

2\uff09COVID-19 \u95a2\u9023\u5bc4\u8a17\u7d30\u80de\u682a \u63d0\u4f9b\u3092\u958b\u59cb\u3057\u307e\u3057\u305f\u3002<\/strong>
\n\n\n\n\n\t\n\n\t\n\t\n\t
Reference<\/th>BRC Resource<\/th>\u7279\u6027<\/th>\n<\/tr>\n<\/thead>\n
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection <\/a> <\/td>RCB5391 R52_Spike<\/a> <\/td>\u6297SARS-CoV-2 Spike\u6297\u4f53(Clone R52)\u3092\u7523\u751f\u3059\u308b\u30cf\u30a4\u30d6\u30ea\u30c9\u30fc\u30de\u3002<\/td>\n<\/tr>\n
RCB5392 S1D7_Spike<\/a> <\/td>\u6297SARS-CoV-2 Spike\u6297\u4f53(Clone S1D7)\u3092\u7523\u751f\u3059\u308b\u30cf\u30a4\u30d6\u30ea\u30c9\u30fc\u30de\u3002<\/td>\n<\/tr>\n
RCB5393 S3D8_Spike<\/a> <\/td>\u6297SARS-CoV-2 Spike\u6297\u4f53(Clone S3D8)\u3092\u7523\u751f\u3059\u308b\u30cf\u30a4\u30d6\u30ea\u30c9\u30fc\u30de\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n
\n

3\uff09BRC\u304b\u3089\u63d0\u4f9b\u3057\u305f\u7d30\u80de\u3092\u5229\u7528\u3057\u305f COVID-19 \u95a2\u9023\u6587\u732e<\/strong>
\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
<\/td>BRC Resource<\/th>Journal<\/th>Reference<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>RCB2202 293T<\/a> <\/td>Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14<\/td>Modulation of TNF-\u03b1-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-\u03b1 production and facilitates viral entry<\/a><\/td>\n<\/tr>\n
2<\/td>RCB0007 HeLa<\/a> <\/td>Bioorg Med Chem Lett. 2017 Jun 15;27(12):2746-2751<\/td>Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor<\/a><\/td>\n<\/tr>\n
3<\/td>RCB0995 MDCK<\/a> <\/td>Clin Infect Dis. 2020 Oct 3;ciaa1517<\/td>Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19<\/a> <\/td>\n<\/tr>\n
4<\/td>RCB0535 RAW 264<\/a> <\/td>Viruses. 2020 Jun 28;12(7):699<\/td>Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2<\/a> <\/td>\n<\/tr>\n
5<\/td>RCB0988 CACO-2<\/a>
\nCSII-CMV-MCS-IRES2-Bsd<\/a> <\/td>		PLoS Pathog. 2021 Jan 21;17(1):e1009233.<\/td>SARS-CoV-2 variants with mutations at the S1\/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells<\/a><\/td>\n<\/tr>\n
6<\/td>RCB0485 LA-N-5<\/a> <\/td>Sci Rep. 2021 Feb 9;11(1):3379<\/td>Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19<\/a><\/td>\n<\/tr>\n
7<\/td>RCB2202 293T<\/a> <\/td>Cell. 2021 Jun 24;184(13):3452-3466.e18<\/td>An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies<\/a> <\/td>\n<\/tr>\n
8<\/td>RCB1902 HSC-4<\/a> <\/td>J Anat. 2021 Jun;238(6):1341-1354<\/td>Expression of SARS\u2010CoV\u20102 entry factors in human oral tissue<\/a><\/td>\n<\/tr>\n
9<\/td>RCB0209 SP2\/0-Ag14<\/a> <\/td>J Biol Chem. Jan-Jun 2021;296:100346<\/td> Potent mouse monoclonal antibodies that block SARS-CoV-2 infection <\/a> <\/td>\n<\/tr>\n
10<\/td>RCB0988 CACO-2<\/a>
\nRCB2202 293T<\/a> <\/td>		Sci Rep. 2021 Mar 8;11(1):5376<\/td> MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2<\/a> <\/td>\n<\/tr>\n
11<\/td>RCB0988 CACO-2<\/a> <\/td>J Virol. 2022 Mar 23;96(6):e0000222
\n(bioRxiv. June 30, 2021)<\/td>		 Host cellular RNA helicases regulate SARS-CoV-2 infection<\/a> <\/td>\n<\/tr>\n
12<\/td>RCB0211 MRC-5<\/a><\/td>Cell Rep Med. 2021 Jun 15;2(6):100311<\/td> Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests<\/a> <\/td>\n<\/tr>\n
13<\/td>RCB2202 293T<\/a><\/td>bioRxiv. August 23, 2021<\/td>The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines<\/a> <\/td>\n<\/tr>\n
14<\/td>RCB0098 A549<\/a> <\/td>Biochemical and Biophysical Research Communications.77, 5 November 2021, Pages 146-151<\/td>Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells<\/a> <\/td>\n<\/tr>\n
15<\/td>HPS0002 253G1<\/a> <\/td>J Toxicol Sci. 2021; 46(9):425-435<\/td>Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing<\/a> <\/td>\n<\/tr>\n
16<\/td>RCB0098 A549<\/a>
\nRCB0988 CACO-2<\/a>
\nRCB1942 HuH-7<\/a> <\/td>		iScience. 2021 Oct 22;24(10):103120<\/td>5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2<\/a> <\/td>\n<\/tr>\n
17<\/td>RCB0771 XTC-YF<\/a> <\/td>Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):477-484<\/td>Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile<\/a> <\/td>\n<\/tr>\n
18<\/td>RCB1168 SKW-3<\/a> <\/td>Commun Biol. 2021 Dec 2;4(1):1365<\/td>Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2<\/a> <\/td>\n<\/tr>\n
19<\/td>RCB0001 Vero<\/a> <\/td>iScience. 2021 Nov 17;103379<\/td>Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2<\/a> <\/td>\n<\/tr>\n
20<\/td>RCB0098 A549<\/a>
\nRCB0988 CACO-2<\/a>
\nHuH-7<\/td>		Nat Commun. 2021 Nov 15;12(1):6602<\/td>SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis<\/a> <\/td>\n<\/tr>\n
21<\/td>RCB4557 HUDEP-2<\/a> <\/td>Nat Genet. 2021 Nov;53(11):1606-1615<\/td>Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus<\/a> <\/td>\n<\/tr>\n
22<\/td>RCB0995 MDCK<\/a> <\/td>J Infect Chemother. 2022 Feb;28(2):252-256.<\/td>Stability of SARS-CoV-2 and influenza virus varies across different paper types<\/a> <\/td>\n<\/tr>\n
23<\/td>RCB0988 CAC0-2<\/a> <\/td>Experimental and Therapeutic Medicine 2022-2-10<\/td> Indigo plant leaf extract inhibits the binding of SARS\u2011CoV\u20112 spike protein to angiotensin\u2011converting enzyme 2
\n <\/a> <\/td>\n<\/tr>\n
24<\/td>NIH3T3<\/td>Cancer Sci. 2022 Aug;113(8):2536-2547<\/td> A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer<\/a> <\/td>\n<\/tr>\n
25<\/td>RCB2202 293T<\/a> <\/td>J Med Chem. 2022 Oct 27;65(20):13852-13865<\/td> Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease<\/a> <\/td>\n<\/tr>\n
26<\/td>RCB2202 293T<\/a>
\nRCB0001 Vero<\/a> <\/td>		Pharm Res. 2022 Sep 26;1-9<\/td> Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-\u03b2 Conjugated Exosomes<\/a> <\/td>\n<\/tr>\n
27<\/td>RCB1637 293<\/a> <\/td>Commun Biol. 2022 Nov 5;5(1):1188<\/td> ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner<\/a> <\/td>\n<\/tr>\n
28<\/i><\/td>RCB2630 B16F10<\/a><\/td>Cell. 2022 Jun 9;185(12):2103-2115.e19<\/td> Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike<\/a><\/td>\n<\/tr>\n
29<\/i><\/td>RCB0098 A549<\/a>
\nRCB2202 293T<\/a><\/td>		J Biol Chem. 2022 Nov;298(11):102500<\/td> Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis<\/a><\/td>\n<\/tr>\n
30<\/i><\/td>RCB0995 MDCK<\/a>
\nRCB2202 293T<\/a><\/td>		J Nat Prod. 2022 Nov 25;85(11):2583-2591<\/td> Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant Streptomyces sp. JA74, Exhibiting Antiviral Activity against Influenza and SARS-CoV-2 Viruses<\/a><\/td>\n<\/tr>\n
31<\/i><\/td>RC2202 293T<\/a><\/td>Sci Transl Med. 2023 Jan 18;15(679):eabq4064<\/td>S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters<\/a><\/td>\n<\/tr>\n
32<\/i><\/td>RC2202 293T<\/a>
\nRCB0001 Vero<\/a><\/td>		iScience. 2023 Jan 20;26(1):105742<\/td>Stimulation of interferon-\u03b2 responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n
\n

4\uff09COVID-19 \u7814\u7a76\u306e\u305f\u3081\u306e\u7d30\u80de\u682a<\/strong>
\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
<\/td>BRC Cell Line<\/th>Cell Line<\/th>Reference<\/th>\n<\/tr>\n<\/thead>\n
1<\/td>Vero E6, RCB0001 Vero<\/a>
\nRCB0988 CACO-2<\/a>
\nCalu-3
\nRCB2202 293T<\/a>
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nCaco-2
\nCalu-3
\nHEK293T
\nHuh7<\/td>		In Vitro and Animal Models for SARS-CoV-2 research<\/a><\/td>\n<\/tr>\n
2<\/td>Vero E6
\nRCB0001 Vero<\/a>
\nRCB1366 HuH-7<\/a>
\nRCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a>
\nEFKB3<\/td>		Vero E6
\nVero
\nHUH 7.0
\n293T
\nA549
\nEFKB3<\/td>		Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States<\/a><\/td>\n<\/tr>\n
3<\/td>RCB0001 Vero<\/a>
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB2202 293T<\/a>
\nRCB1366 HuH-7<\/a>
\n<\/td>		Vero
\nHeLa
\nHEK293T\/F
\nHuh7<\/td>		A Thermostable mRNA Vaccine against COVID-19<\/a><\/td>\n<\/tr>\n
4<\/td>RCB1637 293<\/a>
\nRCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a>
\nRCB0218 MRC-5, known PDL <\/a>
\nVero E6, RCB0001 Vero<\/a>
\nVero 81
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB1366 HuH-7<\/a><\/td>		293
\n293T
\nA549
\nMRC5
\nVero E6
\nVero 81
\nHeLa
\nHuh7<\/td>		Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV<\/a><\/td>\n<\/tr>\n
5<\/td>RCB1648 Hep G2<\/a>
\nRCB1366 HuH-7<\/a>
\nRCB2202 293T<\/a>
\nRCB0001 Vero<\/a>
\nCHO
\nRCB0995 MDCK<\/a>
\n<\/td>		HepG2
\nHuh-7
\n293T
\nVero
\nCHO
\nMDCK<\/td>		Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2<\/a><\/td>\n<\/tr>\n
6<\/td>Vero E6, RCB0001 Vero<\/a>
\nRCB1366 HuH-7<\/a>
\n<\/td>		Vero E6
\nHuh-7<\/td>		Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-\u03baB signaling pathway<\/a><\/td>\n<\/tr>\n
7<\/td>Vero E6, RCB0001 Vero<\/a>
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nHuh-7<\/td>		Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-\u03baB) signaling pathway<\/a><\/td>\n<\/tr>\n
8<\/td>Vero E6, RCB0001 Vero<\/a>
\nRCB1366 HuH-7<\/a>
\n<\/td>		Vero E6
\nHuh-7<\/td>		Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)<\/a><\/td>\n<\/tr>\n
9<\/td>Vero E6, RCB0001 Vero<\/a>
\nRCB1366 HuH-7<\/a><\/td>		Vero E6
\nHuh-7<\/td>		A pneumonia outbreak associated with a new coronavirus of probable bat origin<\/a><\/td>\n<\/tr>\n
10<\/td>RCB1637 293<\/a>
\nRCB1366 HuH-7<\/a>
\nRCB1423 BHK-21<\/a>
\nVero E6, RCB0001 Vero<\/a><\/td>		HEK293
\nHuh-7
\nBHK21
\nVero-E6<\/td>		Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKK\u03b5<\/a><\/td>\n<\/tr>\n
11<\/td>RCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB2202 293T<\/a>
\nRCB1423 BHK-21<\/a>
\nRCB0988 CACO-2<\/a><\/td>		HeLa
\n293T
\nBHK-21
\nCaco-2<\/td>		COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome<\/a><\/td>\n<\/tr>\n
12<\/td>RCB0988 CACO-2<\/a><\/td>Caco-2<\/td>Proteomics of SARS-CoV-2-infected host cells reveals therapy targets<\/a><\/td>\n<\/tr>\n
13<\/td>RCB0988 CACO-2<\/a><\/td>Caco-2<\/td>A metabolic handbook for the COVID-19 pandemic<\/a><\/td>\n<\/tr>\n
14<\/td>RCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a>
\nBHK
\nRCB0988 CACO-2<\/a>
\nRCB1366 HuH-7<\/a>
\nPK-15 <\/td>		293T
\nA549
\nBHK
\nCaco-2
\nHuh-7.5
\nPK-15 <\/td>		Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses<\/a><\/td>\n<\/tr>\n
15<\/td>RCB2202 293T<\/a>
\nRCB0098 A549<\/a>, RCB3677 A549<\/a><\/td>		HEK293T
\nA549 <\/td>		Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza<\/a><\/td>\n<\/tr>\n
16<\/td>RCB2202 293T<\/a>
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nCalu-3
\nRCB0218 MRC-5, known PDL <\/a><\/td>		HEK293T
\nHeLa
\nCalu-3
\nMRC-5<\/td>		Cell entry mechanisms of SARS-CoV-2<\/a><\/td>\n<\/tr>\n
17<\/td>RCB2202 293T<\/a>
\nHEK293F
\nRCB0007 HeLa<\/a>, RCB3680 HeLa<\/a>
\nRCB0218 MRC-5, known PDL <\/a><\/td>		HEK293T
\nHEK293F
\nHeLa
\nMRC5 <\/td>		Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry<\/a><\/td>\n<\/tr>\n
18<\/td>RCB1366 HuH-7<\/a>
\nHuh-7.5<\/td>		Huh-7
\nHuh-7.5<\/td>		Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication<\/a><\/td>\n<\/tr>\n
19<\/td>RCB0994 MA104<\/a>
\nRCB1637 293<\/a><\/td>		MA104
\nHEK293<\/td>		TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes<\/a><\/td>\n<\/tr>\n
20<\/td>RCB0218 MRC-5, known PDL <\/a><\/td>MRC-5 <\/td>Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells<\/a><\/td>\n<\/tr>\n
21<\/td>Fcwf-4
\nA72
\nRCB0995 MDCK<\/a>
\nDH82<\/td>		Fcwf-4
\nA72
\nMDCK
\nDH82 <\/td>		Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663<\/a><\/td>\n<\/tr>\n
22<\/td>GES-1
\nRCB1189 THP-1<\/a>,RCB3686 THP-1<\/a><\/td>		GES-1
\nTHP-1 <\/td>		Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"

1\uff09\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u306b\u5bfe\u3059\u308b\u7406\u7814BRC\u306e\u53d6\u308a\u7d44\u307f \u7406\u7814\u30d0\u30a4\u30aa\u30ea\u30bd\u30fc\u30b9\u7814\u7a76\u30bb\u30f3\u30bf\u30fc(\u7406\u7814BRC)\u306f\u3001\u907a\u4f1d\u5b50\/\u7d30\u80de\/\u30de\u30a6\u30b9\u500b\u4f53\u306e\u4e09\u3064\u306e\u751f\u547d\u968e\u5c64\u306e\u30ea\u30bd\u30fc\u30b9\u30921\u6a5f\u95a2\u3067\u53d6\u308a\u63c3\u3048\u305f\u3001\u4e16\u754c\u7684\u306b\u3082\u30e6\u30cb\u30fc\u30af\u306a\u30ea\u30bd\u30fc\u30b9\u6a5f\u95a2\u3067\u3059\u3002\u3053\u306e\u7279\u5fb4\u3092\u6d3b\u304b\u3057\u3066\u3001\u65b0\u578b\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7\u306e\u7d71\u5408\u7684\u306a\u7814\u7a76\u306e\u4fc3\u9032\u306e\u305f\u3081\u3001\u611f\u67d3\u75c7\u306e4\u3064\u306e\u30b9\u30c6\u30fc\u30b8\uff08\u2460\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u30fb\u5897\u6b96\u3001\u2461\u767a\u75c7\u30fb\u751f\u4f53\u9632\u5fa1\u3001\u2462\u91cd\u75c7\u5316\u3001\u2463\u6cbb\u7642\u30fb\u4e88\u9632\uff09\u306e\u7814\u7a76\u958b\u767a\u306e\u9375\u3068\u306a\u308b\u30d0\u30a4 […]<\/p>\n","protected":false},"author":15,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_mc_calendar":[],"footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-12448","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages\/12448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/comments?post=12448"}],"version-history":[{"count":13,"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages\/12448\/revisions"}],"predecessor-version":[{"id":15296,"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/pages\/12448\/revisions\/15296"}],"wp:attachment":[{"href":"http:\/\/cell.brc.riken.jp\/ja\/wp-json\/wp\/v2\/media?parent=12448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}